Annual report pursuant to Section 13 and 15(d)

Extab Acquisition - Additional Information (Detail)

v3.19.1
Extab Acquisition - Additional Information (Detail) - USD ($)
$ in Millions
Aug. 01, 2017
May 18, 2015
May 14, 2015
Business Acquisition [Line Items]      
Intangible assets, Useful life 6 years 14 years  
Sopharma, AD [Member]      
Business Acquisition [Line Items]      
Percentage of outstanding interests acquired     75.00%
Total cash consideration paid     $ 2.0
Deferred payment     $ 2.0
Additional agreement period     5 years
Amount of outstanding loans paid     $ 0.3
Business acquisition, contingent liabilities     0.0
Fair value attributable to the non-controlling interest     $ 0.7
License agreement expiry date     May 26, 2029
Intangible assets, Useful life     14 years